| Ident. | Authors (with country if any) | Title |
|---|
| 000611 |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study |
| 000920 |
Leon Poltawski [Royaume-Uni] ; Hazel Edwards [Royaume-Uni] ; Amy Todd [Royaume-Uni] ; Tim Watson [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Cherry Ann James [Royaume-Uni] | Ultrasound treatment of cutaneous side‐effects of infused apomorphine: A randomized controlled pilot study |
| 000B30 |
D. Nyholm [Suède] ; R. Constantinescu [Suède] ; B. Holmberg [Suède] ; N. Dizdar [Suède] ; H. Askmark [Suède] | Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations |
| 000E08 |
Pedro J. García Ruiz [Espagne] ; Ángel Sesar Ignacio [Espagne] ; Bego A Ares Pensado [Espagne] ; Alfonso Castro García [Espagne] ; Fernando Alonso Frech [Espagne] ; Mercedes Álvarez L Pez [Espagne] ; José Arbelo González [Espagne] ; Joan Baiges Octavio [Espagne] ; Juan Andrés Burguera Hernández [Espagne] ; Matilde Calopa Garriga [Espagne] ; Dulce Campos Blanco [Espagne] ; Belén Casta O García [Espagne] ; Manuel Carballo Cordero [Espagne] ; José Chac N Pe A [Espagne] ; Anna Espino Ibá Ez [Espagne] ; Aránzazu Gorospe Onisalde [Espagne] ; Santiago Giménez-Roldán [Espagne] ; Pilar Granés Ibá Ez [Espagne] ; Jorge Hernández Vara [Espagne] ; Ram N Ibá Ez Alonso [Espagne] ; Félix Javier Jiménez Jiménez [Espagne] ; Jerzy Krupinski [Espagne] ; Jaime Kulisevsky Bojarsky [Espagne] ; Inés Legarda Ramírez [Espagne] ; Elena Lezcano García [Espagne] ; Juan Carlos Martínez-Castrillo [Espagne] ; Dolores Mateo González [Espagne] ; Francesc Miquel Rodríguez [Espagne] ; Pablo Mir [Espagne] ; Elena Mu Oz Fargas [Espagne] ; José Obeso Inchausti [Espagne] ; Jesús Olivares Romero [Espagne] ; José Olivé Plana [Espagne] ; Pilar Otermin Vallejo [Espagne] ; Berta Pascual Sedano [Espagne] ; Víctor Pérez De Colosía Rama [Espagne] ; Isabel Pérez L Pez-Fraile [Espagne] ; Albert Planas Comes [Espagne] ; Víctor Puente Periz [Espagne] ; María Cruz Rodríguez Oroz [Espagne] ; Dolores Sevillano García [Espagne] ; Pilar Solís Pérez [Espagne] ; José Suárez Mu Oz [Espagne] ; Julia Vaamonde Gamo [Espagne] ; Caridad Valero Merino [Espagne] ; Francesc Valldeoriola Serra [Espagne] ; José Miguel Velázquez Pérez [Espagne] ; Rosa Yá Ez Ba A [Espagne] ; Ivana Zamarbide Capdepon [Espagne] | Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study |
| 000F27 |
Fabio Blandini [Italie] ; Giovanna Levandis [Italie] ; Eleonora Bazzini [Italie] ; Giuseppe Nappi [Italie] ; Marie-Therese Armentero [Italie] | Time‐course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6‐hydroxydopamine in the rat: new clues from an old model |
| 001169 |
Obering [États-Unis] ; Chen ; Swope [États-Unis] | Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease |
| 001339 |
D. De Gaspari [Italie] ; C. Siri [Italie] ; A. Landi [Italie] ; R. Cilia [Italie] ; A. Bonetti [Italie] ; F. Natuzzi [Italie] ; L. Morgante [Italie] ; C B Mariani [Italie] ; E. Sganzerla [Italie] ; G. Pezzoli [Italie] ; A. Antonini [Italie] | Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus |
| 001516 |
Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Hughes [Australie] ; Andrew Evans [Royaume-Uni] ; Alice J. Manson [Royaume-Uni] ; Marion Hoffman [Australie] ; Lesley Swinn [Royaume-Uni] ; Hilary Watt [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges |
| 001579 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study |
| 001936 |
Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients |
| 001C20 |
Arpesh Mehta [États-Unis] ; Kyriaki Thermos [Grèce] ; Marie-Françoise Chesselet [États-Unis] | Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions |
| 002357 |
D. Muguet [France] ; E. Broussolle [France] ; G. Chazot [France] | Apomorphine in patients with Parkinson's disease |
| 002551 |
G. Masson [France] ; D. Mestre [France] ; O. Blin [France] | Dopaminergic modulation of visual sensitivity in man |
| 002553 |
Aj Lees [Royaume-Uni] | Dopamine agonists in Parkinson's disease: a look at apomorphine |
| 002B06 |
Lodovico Frattola [Italie] ; Maria Grazia Albizzati [Italie] ; Sirio Bassi [Italie] ; Carlo Ferrarese [Italie] ; Marco Trabucchi [Italie] | “On‐off” phenomena, dyskinesias and dystonias |
